Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients

Proteasome inhibitors can eliminate malignant, alloreactive, or autoreactive plasma cells. These cells are key players in antibody-mediated autoimmune disorders and thus suitable therapeutic targets for these drugs. However, certain proteasome inhibitors cause toxic peripheral neuropathy in patients...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Marina Mané-Damas, Abhishek Saxena, Gisela Nogales-Gadea, Jo Stevens, Shannen Vincken, Maarten van Beek, Nynke J. van den Hoogen, Elbert A. J. Joosten, Nick Willcox, Hans Duimel, Jos G. Maessen, Peter C. Molenaar, Marc H. De Baets, Mario Losen, Pilar Martinez-Martinez
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2025-05-01
סדרה:	Frontiers in Immunology
נושאים:	ixazomib targeting autoimmune plasma cells myasthenia gravis proteasome inhibition autoantibody therapy
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521432/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!